BioArctic AB and Mesenkia Therapeutics have entered a research collaboration to develop a novel antibody-based treatment for glioblastoma, a highly aggressive brain cancer with limited treatment options. The partnership combines BioArctic's BrainTransporter™ technology, which helps deliver drugs across the blood-brain barrier, with Mesenkia's antibody targeting the HVEM protein on glioblastoma tumor cells. This approach aims to address tumor stem cells that contribute to recurrence and resistance, potentially offering new hope for patients. The companies will conduct preclinical studies to validate the concept and decide on further development steps based on the results.
Sei has started rolling out its Eidos storage upgrade via the v6.6 mainnet update, aiming to rebuild its layer-1 network storage and verification system. This upgrade separates Ethereum Virtual Machine (EVM) state into a dedicated database and introd...
XRP price remains steady near $1, supported above $0.99, amid fading bearish momentum. A significant White House meeting involving President Trump, SEC Chair Paul Atkins, CFTC Chief Michael Selig, and executives from Coinbase, Ripple, and others is s...
The US dollar, though recently supported by higher Treasury yields, faces potential weakening due to growing fiscal risks, softer economic data, and uncertainty over Federal Reserve policy. Strategists note that yields driven by fiscal risk or inflat...
Bitcoin.de, operated by Bitcoin Group SE, has suspended trading and deposits since June 12, 2026, due to a shift from a peer-to-peer marketplace to a broker model and pending regulatory authorization under the EU's MiCAR framework. Customers face unc...
Maya Protocol, a decentralized multi-chain liquidity network, was exploited for about $1.7 million, with 20 BTC (worth $1.34 million) traced to a single wallet and remaining untouched. The protocol, which allows cross-chain asset swaps without centra...
